Menu
No results found.
Weekly Share Price & Valuation Overview
Huadong Medicine Co., Ltd
Huadong Medicine Co., Ltd, together with its subsidiaries, engages in the wholesale and retail of pharmaceutical products in China and internationally. It operates through Pharmaceutical Industry, Pharmaceutical Business, Aesthetic Medicine, and Industrial Microbiology segments. The company distributes Chinese and western medicines, Chinese herbal medicines, and medical instruments; and immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs, antibiotic drugs, medical beauty field products, and medical apparatus and equipment. It also manufactures and sells antibiotics, Chinese patent medicines, synthetic drugs, and genetic engineering drugs; and engages in pharmaceutical logistics and industrial microbiology activities. In addition, the company provides business, leasing, and warehousing services. The company has a strategic cooperation agreement with SynerK PharmaTech (Suzhou) Co., Ltd. to develop the small nucleic acid (siRNA) drug SNK-2726, an angiotensinogen (AGT) for the treatment of hypertension. Huadong Medicine Co., Ltd was incorporated in 1993 and is headquartered in Hangzhou, China.
- ROE ≥15% reflects strong returns on shareholder equity.
- ROA ≥7% shows efficient use of assets.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CNY 75.44B
- Enterprise Value Operating value: market cap + total debt − cash.
- CNY 74.77B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CNY 42.23B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CNY 14.09B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- CNY 5.11B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CNY 24.10
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 2.03
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 2.16%
- Shares Outstanding
- 1.75B
- Float Shares
- 731.40M
- Implied Shares Outstanding
- 1.75B
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
10.62%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
12.10%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
33.37%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
8.44%
- ROA Strong Return on assets: net income ÷ total assets.
-
7.37%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
15.08%
- Revenue Growth Year-over-year revenue growth.
-
3.10%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
5.80%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
6.10%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.17
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.11
- Total Cash Cash and equivalents.
- CNY 3.71B
- Total Debt Short + long-term interest-bearing debt.
- CNY 2.67B
- Net Debt Net Cash Total debt − cash (negative = net cash).
- CNY -1.04B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.52
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CNY 3.40B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- CNY 517.83M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
8.05%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
1.23%
- Cash Conversion (OpCF/EBITDA)
- 0.67
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.